Biomarker · Gene alteration

EGFR mutation (any sensitizing or resistance mutation)

Somatic mutations of the EGFR tyrosine kinase domain detected by sequencing or PCR in tumor tissue or plasma; used as a predictive marker for EGFR tyrosine kinase inhibitors, chiefly in non-small cell lung cancer.

CI-BIO-00000008EGFR graph →NCIt C98357

Also calledEGFR-mutant · EGFR-mutated · EGFR activating mutation

Derived

Associated cancers (20)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Lung Non-Small Cell Carcinoma	152	149	3	—	28 / 52 / 32 / 39 / 1
Lung Adenocarcinoma	46	44	2	—	1 / 18 / 25 / 2 / 0
Malignant Colorectal Neoplasm	17	17	—	—	0 / 5 / 4 / 7 / 1
Malignant Neoplasm	14	14	—	—	0 / 0 / 0 / 14 / 0
Head and Neck Squamous Cell Carcinoma

Derived

Drugs with predictive evidence (39)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
ErlotinibSmall Molecule	99	78	21	A	71 / 21	Colon Adenocarcinoma, Glioblastoma, High-Grade Glioma, NOS, Lung Adenocarcinoma +6
GefitinibSmall Molecule	69	59	10

Curated evidence

Predictive evidence items (252)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 252 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Expression1
Lapatinib

Regulatory

Approvals mentioning the linked drugs (475)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpd

Clinical trials

Active trials (934)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 468 recruiting · 247 active phase 3 · 3,990 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–50 of 934 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	active not recruiting	Phase 2

Literature

Linked publications (141)

Publications linked to the scope gene(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–25 of 141 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

EGFR T790M resistance mutation in non small-cell lung carcinoma.
· Clin Chim Acta · 2015 · PMID 25668228 · validated civic_curation pubmed
Osimertinib: First Global Approval.
· Drugs · 2016 · PMID 26729184 · validated civic_curation pubmed
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
· N Engl J Med · 2017 · PMID 27959700 · validated civic_curation pubmed
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
· Oncologist · 2014 · PMID 24868098 · validated

EGFR Overexpression3
Nimotuzumab	Esophageal Squamous Cell CarcinomaALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID783 55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to mod… (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic
Cetuximab	Head and Neck Squamous Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID692 EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcino… (full text at CIViC) PMID 23265711 · Licitra et al., 2013 · Open in CIViC	civic
Cetuximab + DocetaxelCombination	Head and Neck Squamous Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID849 47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no imp… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC	civic

EGFR VIII5
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID772 49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort o… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC	civic
Erlotinib + GefitinibSubstitutes	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID1128 Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment w… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC	civic
Rindopepimut	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID971 In a Phase II clinical trial, patients with Glioblastoma Multiforme (GBM), positive for EGFR VIII deletion mutation (N=65), were treated with the Rindopepimut cancer vaccine, and standard adjuvant te… (full text at CIViC) PMID 25586468 · Schuster et al., 2015 · Open in CIViC	civic
Cetuximab + DocetaxelCombination	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	2	accepted	EID848 47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression wa… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC	civic
Erlotinib	High-Grade Glioma, NOS	Predictive	D	Supports Sensitivity Response	3	accepted	EID4500 In an in vitro study, a Ba/F3 cell line expressing EGFR vIII demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic

EGFR L858R9
Erlotinib	High-Grade Glioma, NOS	Predictive	D	Supports Sensitivity Response	3	accepted	EID4295 In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assesse… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic
Afatinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID879 A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID883 In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were … (full text at CIViC) PMID 22452895 · Yang et al., 2012 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID982 Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364… (full text at CIViC) PMID 24439929 · Wu et al., 2014 · Open in CIViC	civic
Cetuximab	Lung Adenocarcinoma	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID4292 In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by asse… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID4290 In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 mon… (full text at CIViC) PMID 27032107 · De Grève et al., 2016 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID4291 In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9 ± 12.4nM). EGFR L858R was used as a positive control for comparing sensiti… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Gefitinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID2634 In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response… (full text at CIViC) PMID 22370314 · Han et al., 2012 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID6183 In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy … (full text at CIViC) PMID 27022112 · Urata et al., 2016 · Open in CIViC	civic

EGFR Exon 19 Deletion6
Afatinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID880 A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 9… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID882 In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In to… (full text at CIViC) PMID 22452895 · Yang et al., 2012 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID981 Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364… (full text at CIViC) PMID 24439929 · Wu et al., 2014 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID983 In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemothe… (full text at CIViC) PMID 25589191 · Yang et al., 2015 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	—	accepted	EID4766 In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 d… (full text at CIViC) PMID 27566387 · Kanemaru et al., 2016 · Open in CIViC	civic
Gefitinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID2519 In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response… (full text at CIViC) PMID 22370314 · Han et al., 2012 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Afatinib	CA Health Canada	—	Marketed in Canada as MAR-AFATINIB (DIN 02517035) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 31, 2025	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as MAR-AFATINIB (DIN 02517019) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 31, 2025	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as MAR-AFATINIB (DIN 02517027) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 31, 2025	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as SANDOZ AFATINIB (DIN 02512793) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 28, 2024	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as SANDOZ AFATINIB (DIN 02512777) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 28, 2024	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as SANDOZ AFATINIB (DIN 02512785) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 28, 2024	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as GIOTRIF (DIN 02415682) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 17, 2014	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as GIOTRIF (DIN 02415674) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 17, 2014	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as GIOTRIF (DIN 02415666) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 17, 2014	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as TEVA-AFATINIB (DIN 02514613) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Apr 9, 2025	—	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as TEVA-AFATINIB (DIN 02514591) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Apr 9, 2025	—	health-canada-dpd
Afatinib	CA Health Canada	—	Marketed in Canada as TEVA-AFATINIB (DIN 02514605) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Apr 9, 2025	—	health-canada-dpd
Afatinib	EU EMA	Lung Non-Small Cell Carcinoma	Giotrif as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.	approved	Sep 25, 2013	ema
Afatinib	US FDA	—	Efficacy supplement 2022-04-07 (see label)	approved	Apr 7, 2022	openfda
Afatinib	US FDA	—	Efficacy supplement 2018-01-12 (see label)	approved	Jan 12, 2018	openfda
Afatinib	US FDA	—	Efficacy supplement 2016-04-15 (see label)	approved	Apr 15, 2016	openfda
Afatinib	US FDA	—	Efficacy supplement 2015-11-09 (see label)	approved	Nov 9, 2015	openfda
Afatinib	US FDA	Lung Non-Small Cell Carcinoma	Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy	approved	Jul 12, 2013	openfda
Afatinib	US FDA	Lung Non-Small Cell Carcinoma	First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test	approved	Jul 12, 2013	openfda
Afatinib	US FDA	—	Limitations of Use : Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations	approved	Jul 12, 2013	openfda
Amivantamab	CA Health Canada	—	Marketed in Canada as RYBREVANT SC (DIN 02569175) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 24, 2026	health-canada-dpd
Amivantamab	CA Health Canada	—	Marketed in Canada as RYBREVANT SC (DIN 02569159) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 24, 2026	health-canada-dpd
Amivantamab	CA Health Canada	—	Marketed in Canada as RYBREVANT SC (DIN 02569167) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 24, 2026	health-canada-dpd
Amivantamab	CA Health Canada	—	Marketed in Canada as RYBREVANT SC (DIN 02569140) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 24, 2026	health-canada-dpd
Amivantamab	CA Health Canada	—	Marketed in Canada as RYBREVANT (DIN 02526182) under ATC L01FX18 AMIVANTAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 26, 2022	health-canada-dpd
Amivantamab	EU EMA	Lung Non-Small Cell Carcinoma	Rybrevant is indicated: in combination with lazertinib for the first line treatment of adult patients with advanced non small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations. in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI). in combination with carboplatin and pemetrexed for the first line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations. as monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum based therapy.	approved	Dec 9, 2021	ema
Amivantamab	US FDA	—	Efficacy supplement 2025-08-14 (see label)	approved	Aug 14, 2025	openfda
Amivantamab	US FDA	—	Efficacy supplement 2024-09-19 (see label)	approved	Sep 19, 2024	openfda
Amivantamab	US FDA	—	Efficacy supplement 2024-08-19 (see label)	approved	Aug 19, 2024	openfda
Amivantamab	US FDA	—	Efficacy supplement 2024-03-01 (see label)	approved	Mar 1, 2024	openfda
Amivantamab	US FDA	—	Efficacy supplement 2022-11-04 (see label)	approved	Nov 4, 2022	openfda
Amivantamab	US FDA	Lung Non-Small Cell Carcinoma	Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor [see Dosage and Administration (2.2) ] .	approved	May 21, 2021	openfda
Amivantamab	US FDA	Lung Non-Small Cell Carcinoma	Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] , whose disease has progressed on or after platinum-based chemotherapy.	approved	May 21, 2021	openfda
Amivantamab	US FDA	Lung Non-Small Cell Carcinoma	First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] .	approved	May 21, 2021	openfda
Amivantamab	US FDA	Lung Non-Small Cell Carcinoma	First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT, in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] .	approved	May 21, 2021	openfda
Bevacizumab	CA Health Canada	—	Marketed in Canada as VEGZELMA (DIN 02534177) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 14, 2023	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as VEGZELMA (DIN 02534185) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 1, 2023	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as AYBINTIO (DIN 02522829) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 27, 2022	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as AYBINTIO (DIN 02522837) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 27, 2022	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as ABEVMY (DIN 02522160) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2022	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as ABEVMY (DIN 02522179) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 13, 2022	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as BAMBEVI (DIN 02520729) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 9, 2021	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as BAMBEVI (DIN 02520737) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 9, 2021	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as ZIRABEV (DIN 02489430) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 25, 2019	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as ZIRABEV (DIN 02489449) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 25, 2019	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as MVASI (DIN 02470748) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 1, 2019	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as MVASI (DIN 02470756) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 1, 2019	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as AVASTIN (DIN 02270994) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 2, 2005	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as BEVQOLVA (DIN 02567830) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Bevacizumab	CA Health Canada	—	Marketed in Canada as BEVQOLVA (DIN 02567865) under ATC L01FG01 BEVACIZUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd